MATTHEW K. FUST - Corporate Board Profile

Viracta Therapeutics, Inc.

Filing Date	Source Excerpt
2008-04-29	Consistent with these considerations, after a review of all relevant transactions or relationships between each director, or any of his family members, and Sunesis, our senior management and our independent registered public accounting firm, the Board has affirmatively determined that Drs. Evnin, Fodor, Pearce and Stump and Messrs. Fust, Goldby and Leff, a majority of our Board, are independent directors within the meaning of the applicable NASDAQ listing requirements. ... The Audit Committee is chaired by Mr. Fust, and also includes Dr. Evnin and Mr. Goldby. ... The Compensation Committee is chaired by Dr. Evnin, and also includes Messrs. Goldby and Leff. ... The Nominating and Corporate Governance Committee is chaired by Dr. Fodor, and also includes Mr. Fust and Dr. Pearce.
2009-05-20	Matthew K. Fust has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, since January 2009. ... The Audit Committee is chaired by Mr. Fust, and also includes Mr. Hurwitz and Dr. Stump. ... The Compensation Committee is chaired by Mr. Misfeldt, and also includes Messrs. Hurwitz and Fust. ... The following table sets forth the compensation information for our non-employee directors, ... Matthew K. Fust Fees Earned or Paid in Cash $28,000, Option Awards $17,235, Total $45,235.
2010-04-29	Matthew K. Fust has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc. since January 2009. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business. The Audit Committee is chaired by Mr. Fust, and also includes Mr. Hurwitz and Dr. Stump. On the date of our annual meeting of stockholders each year, each non-employee director who serves on a committee is entitled to receive an annual payment of $3,000 for service as a member on a committee and $5,000 for service as chairman of a committee. Mr. Fust's total compensation for 2009 was $54,684.
2011-04-21	Matthew K. Fust has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, since January 2009. ... The Audit Committee is chaired by Mr. Fust, and also includes Mr. Hurwitz and Dr. Stump. ... The following table sets forth the compensation information for our non-employee directors, as well as Dr. Young, the current Chairman of our Board and former Executive Chairman, for the year ended December 31, 2010. ... Matthew K. Fust Fees Earned or Paid in Cash $45,000, Option Awards $5,393, Total $50,393.
2012-04-23	Matthew K. Fust has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc. The Board has concluded that Mr. Fust should serve on our Board due to his financial expertise. The Audit Committee is chaired by Mr. Fust. Director Compensation Table shows total compensation of $117,690.
2013-04-25	Matthew K. Fust has been Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, since January 2009. ... The Audit Committee is chaired by Mr. Fust, and also includes Ms. Kim and Dr. Stump. ... The Compensation Committee is chaired by Mr. Misfeldt, and also includes Mr. Fust. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2012. ... Matthew K. Fust total compensation $95,480.
2014-04-24	Matthew K. Fust serves as Chairman of the Audit Committee and is a member of the Compensation and Nominating and Corporate Governance Committees. The compensation table shows total compensation of $121,046 for 2013.
2015-04-28	Matthew K. Fust is a board member and advisor to life sciences companies. He retired as Executive Vice President and Chief Financial Officer at Onyx Pharmaceuticals, Inc., a biopharmaceutical company, where he served from January 2009 to October 2013. Prior to joining Onyx, Mr. Fust was Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals, Inc., a pharmaceutical company, which he joined in May 2003. From May 2002 to May 2003, Mr. Fust was Chief Financial Officer at Perlegen Sciences, Inc., a biotechnology company. From June 1996 to January 2002, Mr. Fust was with ALZA Corporation, first as Controller and then as Chief Financial Officer. In addition, Mr. Fust serves as a member of the board of directors of MacroGenics, Inc., a biopharmaceutical company, and Ultragenyx Pharmaceutical Inc., a biotechnology company, Dermira, Inc., a biotechnology company and Atara Biotherapeutics, a biotechnology company. Mr. Fust holds a B.A. in Accounting from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business. The Board has concluded that Mr. Fust should serve on our Board due to his financial expertise, in particular with its focus on the pharmaceutical and biopharmaceutical industries. This expertise makes him an important resource for the Board in its oversight of our financial operations and related reporting. Director Compensation Table: Matthew K. Fust Fees Earned or Paid in Cash ($): $67,500, Option Awards ($): $87,038, Total ($): $154,538.
2016-04-25	Matthew K. Fust serves on the Audit Committee, Compensation Committee (Chairman), and Nominating and Corporate Governance Committee. The Director Compensation Table shows total compensation of $152,152.
2017-04-20	Matthew K. Fust is currently a Class III director, but will not stand for reelection at the Annual Meeting. ... The following table sets forth the compensation information for our non-employee directors for the year ended December 31, 2016. Matthew K. Fust received total compensation of $89,240.